KR20220101071A - 새로운 화합물 - Google Patents

새로운 화합물 Download PDF

Info

Publication number
KR20220101071A
KR20220101071A KR1020227008929A KR20227008929A KR20220101071A KR 20220101071 A KR20220101071 A KR 20220101071A KR 1020227008929 A KR1020227008929 A KR 1020227008929A KR 20227008929 A KR20227008929 A KR 20227008929A KR 20220101071 A KR20220101071 A KR 20220101071A
Authority
KR
South Korea
Prior art keywords
methyl
imidazol
urea
phenyl
thienylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227008929A
Other languages
English (en)
Korean (ko)
Inventor
토마스 펙스
벵트 올슨
Original Assignee
바이코어 파마 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68425648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220101071(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이코어 파마 아베 filed Critical 바이코어 파마 아베
Publication of KR20220101071A publication Critical patent/KR20220101071A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227008929A 2019-09-20 2020-09-18 새로운 화합물 Pending KR20220101071A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds
GB1913603.5 2019-09-20
PCT/GB2020/052261 WO2021053344A1 (en) 2019-09-20 2020-09-18 New compounds

Publications (1)

Publication Number Publication Date
KR20220101071A true KR20220101071A (ko) 2022-07-19

Family

ID=68425648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008929A Pending KR20220101071A (ko) 2019-09-20 2020-09-18 새로운 화합물

Country Status (15)

Country Link
US (2) US12435072B2 (cg-RX-API-DMAC7.html)
EP (1) EP4031240A1 (cg-RX-API-DMAC7.html)
JP (2) JP7771049B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220101071A (cg-RX-API-DMAC7.html)
CN (1) CN114786774A (cg-RX-API-DMAC7.html)
AU (2) AU2020351301C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003130A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152218A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000656A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022003091A2 (cg-RX-API-DMAC7.html)
GB (1) GB201913603D0 (cg-RX-API-DMAC7.html)
IL (1) IL291172A (cg-RX-API-DMAC7.html)
MX (2) MX2022003286A (cg-RX-API-DMAC7.html)
PH (1) PH12022550564A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021053344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
JP2024511453A (ja) * 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンii受容体リガンド
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
CA3222721A1 (en) * 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
WO2023193733A1 (zh) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 一种at2r激动剂
WO2024133942A1 (en) 2022-12-22 2024-06-27 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
CN120569378A (zh) * 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE19920815A1 (de) 1999-05-05 2000-11-09 Aventis Pharma Gmbh 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
JP4707321B2 (ja) 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンiiアゴニストとして有用な三環式化合物
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) * 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
ES2834430T3 (es) 2013-03-15 2021-06-17 Univ Southern California Procedimientos, compuestos y composiciones para el tratamiento de enfermedades relacionadas con la angiotensina
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Also Published As

Publication number Publication date
US12435072B2 (en) 2025-10-07
JP7771049B2 (ja) 2025-11-17
US20220388994A1 (en) 2022-12-08
AU2020351301B2 (en) 2026-02-12
MX2022003286A (es) 2022-04-12
CN114786774A (zh) 2022-07-22
AU2020351301A1 (en) 2022-03-17
AU2020351301C1 (en) 2026-08-06
MX2025000262A (es) 2025-02-10
JP2022549086A (ja) 2022-11-24
IL291172A (en) 2022-05-01
AU2026203399A1 (en) 2026-05-21
PH12022550564A1 (en) 2023-03-20
EP4031240A1 (en) 2022-07-27
WO2021053344A1 (en) 2021-03-25
BR112022003130A2 (pt) 2022-05-17
CL2022000656A1 (es) 2022-11-04
CO2022003091A2 (es) 2022-04-19
US20260028333A1 (en) 2026-01-29
CA3152218A1 (en) 2021-03-25
JP2026041728A (ja) 2026-03-10
GB201913603D0 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
US12435072B2 (en) Compounds
US11390616B2 (en) Apelin receptor agonists and methods of use
KR20140040774A (ko) 이미다조피리딘 화합물
US12441718B2 (en) Selective angiotensin II compounds
IL300582A (en) New compounds for use in the treatment of angiotensin II-related diseases
GB2605148A (en) New compounds
EP4648850A1 (en) Selective angiotensin ii compounds
WO2022200787A1 (en) Selective angiotensin ii receptor ligands
WO2022200785A1 (en) Selective angiotensin ii receptor ligands
EA048147B1 (ru) Новые соединения
CN117222624A (zh) 选择性血管紧张素ii受体配体
CN117916229A (zh) 新型选择性血管紧张素ii化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000